An observational study in Pregnancy Related, Pregnancy Loss and Pregnancy Complications, sponsored by The Hospital for Sick Children. Active, not recruiting at 2 sites in Canada. Open to female participants aged Up to 28 Years. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by The Hospital for Sick Children · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Pregnancy Complications with a site in Canada — 5 open to participants now, 11 under way, none of them phase 3. Pregnancy Complications · Canada.
Among the 24 studies in Pregnancy Complications with a site in Canada, this one is one of 3 that started in 2023, is one of 9 observational ones, reaches primary completion later than 8 of the 10 other live ones, and was the 17th registered.
411 studies on the registry are indexed under Pregnancy Complications; 111 are open to participants now.
Browse Pregnancy Complications studies →5 of the 24 studies in Pregnancy Complications with a site in Canada are open now. Recruiting first, the newest first:
Guilherme Sant'Anna, MD · Sites in Canada, Brazil, Italy and 1 more country
Ages 35 wk–42 wk · Healthy volunteers
McMaster University · Sites in Canada
Ages 18–55 · Women only
David Ware Branch · Sites in Canada, United States
Ages 18–40 · Women only
CHU de Quebec-Universite Laval · Sites in Canada
Ages 18+ · Women only · Healthy volunteers
Mount Sinai Hospital, Canada · Sites in Canada, United States
Ages 16–60 · Women only
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 90 Pregnancy Complications studies recruiting now, 43 (48%) set no upper age limit and 44 (49%) stop at 75 or younger; 22 take children under 18; 35 take healthy volunteers.
This study: Up to 28 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800 is above the median of 400 across 198 observational studies indexed under Pregnancy Complications.
Median enrollment 82 across the 15 interventional studies, 400 across the 9 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 24 has an industry lead sponsor. The 10 most frequent:
The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 81 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.
The Hospital for Sick Children has 2 studies filed under Pregnancy Complications — fewer than ten, so there is no comparison to draw.
4 of the studies in Pregnancy Complications with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06529042Mount Sinai Hospital, CanadaSCRIPT: Sickle Cell Risk in Pregnancy Tool | 2026-12 |
| NCT05114096McMaster UniversitySingle Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS) | 2026-12-31 |
| NCT04992104The Hospital for Sick ChildrenMicrobiome and Malnutrition in Pregnancy | 2027-03 |
| NCT06693817Guilherme Sant'Anna, MDAdvanced Wireless Sensors for Neonatal Care in the Delivery Room | 2027-07-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 24 studies in Pregnancy Complications with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is being conducted to investigate how a mother's nutritional status and her gut microbiome during pregnancy contribute to the birth outcomes and health of her baby. The gut microbiome is the totality of microorganisms (e.g. bacteria, viruses, fungi) living in the gastrointestinal tract. This study will focus on pregnant women, 28 years and younger living in the Toronto and greater Toronto area. The focus is on younger women due to their vulnerability to undernutrition. Pregnant participants, and upon delivery, their newborns will be followed throughout pregnancy and for a year afterwards. Throughout this period, the investigators will collect stool samples, rectal swabs, blood samples, health assessments, nutritional and dietary assessments and birth/ labour details. The goal is to define the relationship between a mother's nutritional status and her microbiome dynamics during pregnancy and how they contribute to the birth outcomes and growth of her newborn. With the hypothesis that alterations of the microbiota in the maternal gut (dysbiosis) exacerbated by nutritional status or pathogen exposure during pregnancy, impacts weight gain because of impaired nutrient absorption, leading to corresponding negative birth outcomes.
This project represents the first systematic investigation of the impact of the microbiome on nutritional status during pregnancy in young women and directly aligns with global health initiatives focused on this vulnerable cohort. The goal of the study is to define the relationships between host nutritional status and microbiome dynamics during pregnancy and how they contribute to birth outcomes. The gut microbiome has a profound influence on host nutritional status. Dysbiosis (loss of diversity/beneficial microbes and gain of pathobionts) has emerged as a major factor in the development of undernutrition. Despite the importance of nutrition during pregnancy, few studies have examined the role of the microbiome on maternal health and birth outcomes. Further, little is known concerning the influence of enteric eukaryotic microbes, such as parasites, on the bacterial microbiome and host nutrition.
At the core of this study are two complementary cohorts of young women that provide an exceptional opportunity to obtain longitudinal samples to monitor the dynamic relationships between microbiome community structure and function with gut health and host nutritional status. This registration is for the the Toronto cohort of the study, which will focus on refugee and young adult obstetric clinics in Toronto, a population of specific relevance to undernutrition. This cohort is expected to yield insights into the influence of eukaryotic microbes that are often viewed as asymptomatic. The target demographic of the study is young mothers, 28 years of age and younger, in the Toronto and Greater Toronto Area. The investigators have identified this younger demographic due to the lack of knowledge on the microbiome of young women, and their vulnerability to undernutrition. A second complementary cohort will be based in the Matiari district of Pakistan. This project will yield unprecedented insights into the relationships between prokaryotic and eukaryotic microbes in the gut and their associations with maternal health and birth outcomes.
The central hypothesis of the study is that alterations of the microbiota in the maternal gut (dysbiosis) exacerbated by nutritional status or pathogen exposure during pregnancy, impacts weight gain because of impaired nutrient absorption, leading to corresponding negative birth outcomes.
The study will be a prospective, longitudinal, observational study to investigate the impact and relationship between prokaryotic and eukaryotic microbes in the gut and their association with maternal health and birth outcomes among young women, 28 years of age and younger in the Toronto and Greater Toronto Area. The study will aim to recruit 400 women into two groups based on BMI at time of recruitment (Normal BMI will be defined as between 20 and 24.9 kg/m2 and Low BMI will be defined as less than 20 kg/m2). With a goal of having 200 participants within the normal BMI group and 200 participants within the low BMI group. Although this is the recruitment aim, in the event that the investigators are unable to recruit 200 women with a low BMI, more women will be recruited that fall within the normal BMI range. The study will follow women and their infants over the course of their pregnancy and for a year post-partum, collecting stool, rectal and blood samples, nutritional information, heath assessments, anthropometric measurements and empowerment metrics at different time points.
The study population will consist of pregnant women, 28 years of age and younger, living in the Toronto and Greater Toronto Area. The investigators focus on younger women, due to the lack of knowledge about their microbiome and their vulnerability to undernutrition
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
To assess if alterations of the microbiota in the maternal gut (dysbiosis) are associated with changes in maternal gestational weight gain.
The primary endpoint will be the change in maternal gestational weight gain (GWG) during pregnancy, measured between the first (8-20 weeks post-conception) and second time point (30-34 weeks post conception).
Time frame: 8-20 weeks post-conception, 30-34 weeks post conception
Anthropometrics: Maternal BMI
calculated using weight and height; BMI = kg/m2
Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, delivery, 3-months post-partum, 6 months post-partum and 12 months post-partum
Anthropometrics: Maternal middle upper arm circumference
Measured in cm
Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, 3-months post-partum,and 12 months post-partum
Anthropometrics: Maternal triceps skinfold thickness
Measured in cm
Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, 3-months post-partum, and 12 months post-partum
Anthropometrics: Maternal height
Measured in cm
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, delivery, 3 months post-partum and 12 months post partum
Anthropometrics: Maternal weight
Measured in kg
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, delivery, 3 months post-partum and 12 months post-partum
Maternal blood biomarkers
Concentration of HB + MCV, ferritin, and CRP
Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, and 12 months post-partum
Infant blood biomarkers
Concentration of HB + MCV, ferritin, and CRP
Time frame: 12 months
Infant sex
Female or Male
Time frame: Determined at delivery
Infant morbidity
Assessed through infant health assessment questionnaires
Time frame: 3 months, 6 months and 12 months
Maternal morbidity
Assessed through health assessment questionnaires
Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, 3 months post-partum, 6 months post-partum and 12 months post-partum
Infant growth: weight
Measured in kg
Time frame: within 24 hours of birth, 3 months, 6 months and 12 months
Infant growth: length
Measured in cm
Time frame: within 24 hours of birth, 3 months, 6 months and 12 months
Infant growth: head circumference
Measured in cm
Time frame: within 24 hours of birth, 3 months, 6 months and 12 months
Infant growth: mid upper arm circumference
Measured in cm
Time frame: within 24 hours of birth, 3 months, 6 months and 12 months
Infant growth: triceps skinfold thickness
Measured in cm
Time frame: within 24 hours of birth, 3 months, 6 months and 12 months
Infant Gestational age
Will be documented at baseline visit.
Time frame: 8-20 weeks post conception
Breast feeding: amount and initiation of complementary feeding
Based off of WHO 2010 Guidelines: Indicators for assessing infant and young child feeding practices (Part 2 Measurement)
Time frame: within 24 hours of birth, 3 months, 6 months and 12 months
Maternal age
28 years or younger
Time frame: Documented at 8-20 weeks post-conception
Reported maternal medication use
\[Questionnaire\]
Time frame: 8-20 weeks post-conception, 30-34 weeks post-conception, within 24 hours of delivery, 3-months post-partum, 6 months post-partum and 12 months post-partum
Reported Infant medication use
\[Questionnaire\]
Time frame: within 24 hours of birth, 3 months, 6 months and 12 months
Maternal dietary intake
Assessed through ASA 24 HR Dietary Recall system, completed 2x each time point
Time frame: 8-20 weeks post conception, 30-34 weeks post conception and 12 months post partum
Dietary diversity
Minimum Dietary Diversity Score for Women (MDD-W)
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post-partum and 12 months post partum
Household annual food insecurity
Food insecurity will be assessed using the Household Food Insecurity Access Scale (HFIAS)
Time frame: 3 months post-partum and 12 months post-partum
Self-efficacy
Self-efficacy will be measured using the Generalized Self-Efficacy scale, developed by Schwarzer and Jerusalem
Time frame: 3 months post-partum and 12 months post partum
Perceived decision making
Questions pertaining to perceived decision-making are from the Pakistan Demographic and Health Survey (PDHS)
Time frame: 3 months post-partum and 12 months post partum
Perceived social support
Perceived social support will be measured using the Multi-dimensional Scale of Perceived Social Support (MSPSS), developed by Zimet et al.
Time frame: 3 months post-partum and 12 months post partum
Maternal demographics
Questions pertaining to demographic data are adapted from the Pakistan Demographic and Health Survey (PDHS)
Time frame: 8-20 weeks post-conception
Food insecurity
Questionnaire developed by Hager, E.R., et al., Development and validity of a 2-item screen to identify families at risk for food insecurity.
Time frame: 8-20 weeks post conception, 3 months post partum and 12 months post partum
Perceived parental stress
Perceived parental stress will be measured using the Perceived Stress Scale (PSS-10)
Time frame: 3 months post-partum and 12 months post partum
Preterm birth
noted in labor and birth chart review
Time frame: Within 24 hours of birth
Stillbirth
noted in labor and birth chart review
Time frame: Within 24 hours of birth
Small for gestational age
noted in labor and birth chart review
Time frame: Within 24 hours of birth
Large for gestational age
noted in labor and birth chart review
Time frame: Within 24 hours of birth
Birth size: length
Measured in cm
Time frame: within 24 hours of birth
Birth size: head circumference
Measured in cm
Time frame: within 24 hours of birth
Birth size: weight
Measured in kg
Time frame: within 24 hours of birth
Birth defects
Assessed within 24 hours of birth
Time frame: within 24 hours of birth
Delivery assessment
Assessed within 24 hours of birth
Time frame: within 24 hours of birth
Infant dietary intake: NutricheQ Questionnaire
NutricheQ questionnaire: a tool designed for toddlers aged 1 to 3 years of age, with a focus on markers for inadequate or excessive intake and dietary imbalances
Time frame: 12 months
Maternal stool biomarkers: Calprotectin, Lipocalin and Claudin 15
Markers in the stool for intestinal mass, inflammation, and gut permeability and circulating lipopolysaccharide, among other markers
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Infant Stool biomarkers: Calprotectin, Lipocalin and Claudin 15
Markers in the stool for intestinal mass, inflammation, and gut permeability and circulating lipopolysaccharide, among other markers
Time frame: 3 months and 12 months
Maternal: incidence of pathobionts
As identified through 16S, 18S and ITS rDNA surveys
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Infant: incidence of pathobionts
As identified through 16S, 18S and ITS rDNA surveys
Time frame: 3 months and 12 months
Maternal: metabolomic profile of stool (metabolites involved in central metabolism as analysed by Mass Spectrometry)
Analysis of the core metabolites involved in central metabolism. These metabolites will be analysed through Mass Spec and include short chain fatty acids, amino acids, intermediates in energy metabolism and nucleotide biosynthesis
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Maternal gut bacteria profile as measured through 16S rDNA sequence surveys
measured through 16S rDNA sequence surveys
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Maternal: blood metallomics profile as measured through ICP-MS (https://www.metabolomicscentre.ca/new_service/25)
TMIC Metallomics Platform to be used.
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, and 12 months post partum
Infant: blood metallomics profile as measured through ICP-MS (https://www.metabolomicscentre.ca/new_service/25)
Through TMIC platform
Time frame: 12 months
Infant: gut bacterial profile as measured through 16S rDNA sequence surveys
measured through 16S rDNA sequence surveys
Time frame: 3 and 12 months post partum
Maternal metabolic pathway expression profile as measured through whole microbiome RNASeq (metatranscriptomics)
measured through whole microbiome RNASeq (metatranscriptomics)
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Infant eukaryotic microbiome profile as measured through 18S and ITS rDNA sequence surveys
measured through 18S and ITS rDNA sequence surveys
Time frame: 3 months and 12 months
Maternal eukaryotic microbiome profile as measured through 18S and ITS rDNA sequence surveys
measured through 18S and ITS rDNA sequence surveys
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Maternal bacterial gene expression profile as measured through whole microbiome RNASeq (metatranscriptomics)
The output of these analyses are readouts of microbial gene expression detailing biochemical activities as well as the taxa responsible.
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Maternal: microbiome taxonomic alpha and beta diversity
To define taxonomic diversity, species profiles from 16S, 18S and ITS rDNA data will be clustered to identify differences in community structure across samples. Alpha diversity will be measured through indices such as Chao, Shannon and Simpson indices. Beta diversity will be measured through standard indices such as Bray-Curtis distances.
Time frame: 8-20 weeks post conception, 30-34 weeks post conception, 3 months post partum and 12 months post partum
Infant: microbiome taxonomic alpha and beta diversity
To define taxonomic diversity, species profiles from 16S, 18S and ITS rDNA data will be clustered to identify differences in community structure across samples. Alpha diversity will be measured through indices such as Chao, Shannon and Simpson indices. Beta diversity will be measured through standard indices such as Bray-Curtis distances.
Time frame: 3 months and 12 months
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — In addition to publishing findings in open access journals, the investigators will ensure all sequences and metabolomics datasets are deposited in appropriate public repositories. SOPs, pathogen samples and statistical methods developed through this project will be shared with the IMPACTT research core (https://www.impactt-microbiome.ca/). Microbiome sequence data will be uploaded on the National Centre for Biotechnology Information (NCBI). The NCBI acts as a central data repository for sequence data. In line with publication standards, the investigators are required to provide access to users who may wish to follow up on analyzing the microbiome data for their own purposes. The sample analysis information, including the sequencing data and metabolomics data will be de-identified and the patient sequence data will be removed.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: All sequence and metabolomics data will be made available within 12 months of study completion Supporting information will be shared at time of request
Access criteria: Supporting information will be shared upon request Sequence and metabolomics datasets will be made available without restriction
Started Feb 2023 (actual). Primary completion is estimated for Mar 2027, 49 months after the start.
Of 113 non-industry observational studies under Pregnancy Complications, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 201. This study's planned 49 months is below that.
Counting every sponsor, half of 121 studies reached it within 60 months; a quarter within 30 and three quarters within 201.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Hospital for Sick Children →